| protein
| direct target of LEFTY1 (cooperation of Kruppel-like factor 4 (KLF4) cooperates with POU5F1 and and SOX2 to activate LEFTY1 expression) |
|
ZNF281 directly activate NANOG expression by binding to a site in the promoter in very close proximity to the POU5F1 and SOX2 binding sites  |
|
interacting with KPNA2 |
|
POU5F1 and WDR5 are partners in transcriptional regulation |
|
acts as a transcriptional suppressor of MYOD1 gene expression through its interaction with the upstream enhancer region |
|
involved in the synergistic activation of NANOG, that requires a multisubunit stem cell coactivator complex (SCC) |
|
SOX2 cooperates with POU5F1 to activate downstream target genes by binding to Oct-Sox enhancers |
|
NR5A2 acts as a transcriptional activator in the regulation of POU5F1 gene expression through the cooperative interaction with three binding sites directly or/and indirectly |
|
MBD6 was detected as an POU5F1 regulatory gene |
|
CDK1 and POU5F1 interplay to inhibit ES cell differentiation into trophectoderm and thereby maintain stemness |
|
ITCH interacts with and targets pluripotency-associated transcription factor POU5F1 for ubiquitination |
|
can upregulate BIRC5 and CCND1 expression by increasing their promoter activity, and these factors collusively promotes hepatocellular carcinoma cell proliferation |
|
genomic redistribution of POU5F1 by alternative partnering with SOX2 and SOX17 is a fundamental regulatory event of endodermal specification |
|
its post-translational modifications form a positive feedback loop, which promote AKT1 activation and interaction with HMGB2 and the SET Complex |
|
chromatin regulators EP300, KDM5A, KDM6A and KDM6B cooperate with KLF4 in promoting the transcription of POU5F1 |
|
TAF4B cooperates with POU5F1 to regulate a subset of genes in ESC, whereas TAF4 is required for later embryonic developmental stages |
|
regulates the proper splicing of transcripts encoding for pluripotency regulators such as POU5F1, PRDM14, E4F1 and MED24 |
|
DIDO1 could target to the loci of pluripotency factors such as NANOG and POU5F1 and positively regulate their expression |
|
oncogenic factor ETV4 regulates POU5F1 gene expression as a transcriptional activator |
|
affects the metastatic potential of breast cancer cells through RND1-mediated effects that influence cell motility and E-cadherin expression |
|
TRIM32 modulates pluripotency entry and exit by directly regulating POU5F1 stability |
|
DPF2 decreases monomeric and mono-ubiquitinated POU5F1, assembles poly-ubiquitin chains on POU5F1 mainly through Ub-K48 linkage |
|
NACC1 coordinates differentiation by activating POU5F1 and inhibiting both SOX2 and TCF3 |
|
DPF2, also named ubi-d4/requiem (REQU), interacts with a protein complex containing POU5F1 |
|
novel roles for PCGF6 in directly regulating POU5F1, NANOG, SOX2, and LIN28A expression to maintain ESC identity |
|
dynamic interplay between POU2F1 and POU2F5, in particular during the critical window immediately after loss of pluripotency when cells make the earliest developmental fate decisions |
|
HELLS assists gene repression upon binding to the POU5F1 promoter region |
| Other morbid association(s)
|
| Type | Gene Modification | Chromosome rearrangement | Protein expression | Protein Function
|
|---|
| tumoral
|
|
|
| gain of function
| |
differentially up-regulated in germ cells seminomas | | tumoral
|
|
| --over
|
| |
in carcinoma in situ/gonadoblastoma, seminomas/germinoma/dysgerminoma, and embryonal carcinoma undifferentiated, and in breast cancer | | tumoral
| fusion
|
|
|
| |
wirh EWSR1 in t(6;22)(p21;q12) associated with bone and soft-tissue tumours resulting in a chimaeric molecule fusing the NTD (N-terminal domain) of the EWSR1 to the CTD (C-terminal domain) of POU5F1 embryonic gene | |
